LMAT - Is This Underfollowed Dividend Stock a Buy?
Rising interest rates and fears of a global recession spooked investors, crushing many growth stocks in 2022. The sell-off helped lower the Nasdaq Composite roughly 30% so far this year.
But not all growth stocks fared as poorly as those that dominate the tech-heavy index. Shares of medical device maker LeMaitre Vascular (NASDAQ: LMAT) are down just 12% so far in 2022. The company was helped by the continued strong demand for medical devices even as the economy started slowing.
Does that make LeMaitre Vascular's stock a buy for dividend growth investors? Let's drill down into the company's fundamentals and valuation to try to answer this question.
For further details see:
Is This Underfollowed Dividend Stock a Buy?